Alternative of treatments in prostate cancer in Pinar del Río, 2003-2006

Authors

  • Pedro Ricardo Hernández Campo Especialista de Primer Grado en Medicina General Integral y de Segundo Grado en Urología. Profesor auxiliar. Investigador Agregado. Hospital Clínico-Quirúrgico "León Cuervo Rubio". Pinar del Río.
  • Ileana de Armas Ampudia Especialista de Primer Grado en Medicina General Integral y Urología. Instructora. Hospital Clínico-Quirúrgico "León Cuervo Rubio". Pinar del Río.
  • Idelma Castillo García Especialista de Primer Grado en Urología. Asistente. Investigadora Agregada. Hospital Clínico-Quirúrgico "León Cuervo Rubio". Pinar del Río.
  • Verónica Castillo Pérez Especialista de Primer Grado en Anestesia y Reanimación. Profesora Auxiliar Cirugía general. Hospital Clínico-Quirúrgico "León Cuervo Rubio". Pinar del Río.
  • Teresita Llera Clausell Especialista de Primer Grado en Urología. Profesora Auxiliar de la cátedra de Urología. Hospital Clínico-Quirúrgico "León Cuervo Rubio". Pinar del Río.

Abstract

Scientists have controversial ideas regarding the different choices of treatment for prostate cancer and are exploring new treatment programs and combining ways. An observation, longitudinal, retrospective and descriptive research was conducted in Pinar del Rio during January 1st, 2003 to December 31st, 2006. All patients following the treatment in the office of urology-oncology were included in the research, the evolution of a total of 265 patients was observed trough the value of Specific Prostatic Antigen. To precise the degree of homogeneity in the behavior of the variables a table to distribute frequency was drawn, calculating confidence interval; main results showed that: a number of patients were diagnosed during 2004, a decrease in diagnosis; however attendance to the offices increased. Total Androgenic Blocking Therapy prevailed. During this type of treatment the SPA presents a normal value; the majority of patients achieve normal SPA at 6 months, being this therapy the most effective in prostate cancer.

Downloads

Download data is not yet available.

References

1. Camacho Rodríguez R, Fernández Garrote L, Martín García A, Abascal Ruiz ME, Diez Cabrera. El programa nacional del control del cáncer en Cuba. Rev. Cubana Med Gen Integr. 1994; 10(3):215-9

2. Díaz Alonso G. Epidemiología del cáncer de Próstata. Rev Cubana Ged Gen Integr 1995; 11(4): 378-81.

3. Ministerio de Salud Pública. Grupo Nacional de Oncología. Reunión Nacional de Consenso de elaboración de las guías de diagnóstico y tratamiento del cáncer prostático: Cáncer de próstata, Información general. Ciudad Habana: MINSAP; 2000.

4. Greene KL, Meng MV, Elkin EP. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2005; 171 (6): 2255-9.

5. Ministerio de salud pública. Anuario estadístico. La Habana: MIPSAP; 2005.

6. Delongchamps NB, Singó A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control.2006; 13(3): 158-68.

7. Galán Y, Álvarez ME, Guerra L, Priscila Torres B, Mariela García J, Fernández Garrote L et al. Mortality and Survival from Prostate Cancer in Cuba, 1977-1999. European Journal of Cancer Prevention. 2004; 13(5): 377-381.

8. Konski A , Eisenberg D , Horwitz E , Hanlon A , Pollack A , Hanks G et al. Does age matter in the selection of treatment for men with early-stage prostate cancer? Cancer. 2006; 106(12): 2598-602.

9. López MA, Grosman H, Bellora OG, Surur DM, Grispon D et al. Epidemiologia del cancer de prostata en la óptica de una campaña de detección temprana. Rev. Argent Urol. 2004; 69(4): 210-219.

10. Instituto Nacional de Oncología. "Propuesta para abordar el problema Cáncer de Próstata". La Habana: Minsap; 2006.

11. Grau Abalo JA, Chacón Roger M. Comunicación y apoyo al enfermo: herramientas básicas del acompañamiento. En Material II Congreso Internacional de Tanatología. México: DF: 2006.

12. Peeters ST, Heemsbergen WD, Koper PC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006. 24 (13): 1990-6.

13. Zietman AL, DeSilvio ML, Slater JD. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA .2005; 294 (10): 1233-9.

14. Johansson JE, Andrén O, Andersson SO. Natural history of early, localized prostate cancer. JAMA 291. 2004; (22): 2713-9.

15. Culig Z, Bartsch G, Hobisch A. Antiandrogens in prostate cancer endocrine therapy. Curr Cancer Drug Targets 2004; 4(5): 455-61.

16. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007; 39(9): 1562-8.

17. Sweat GT. Guiding prostate cancer treatment choices. Early detection means more options for more men. Postgrad Med.2005; 117(4): 45-50.

18. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA.2008; 299(3): 289-95.

19. Shelley M, Wilt TJ, Coles B. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev .2007 ;( 3): 5010.

20. Uchida T. High intensity focused ultrasound for localized prostate cancer. Nippon Rinsho.2005; 63(2): 345-9.

21. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005; 24 915): 2474-82.

22. Cury F, Biagini L, Souhami L. Hypofractionated radiotherapy in the management of prostatic cancer. Rev Bras Cancerol. 2004; 50(3): 239-249.

23. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007.Urology. 2007; 70(6): 3-8.

24. Ditan ZA, Bianco FJ, Rabbani F, Eastham JA, Fearn P, Scher HI. Patter of prostate specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol .2005; 23(9): 1962-8.

25. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz Martínez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol .2005; 173(5): 1456-62.

26. Harzstark AL, Ryan CJ. Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs. 2008; 17(1): 13-22.

Downloads

Published

2010-03-19

How to Cite

1.
Hernández Campo PR, de Armas Ampudia I, Castillo García I, Castillo Pérez V, Llera Clausell T. Alternative of treatments in prostate cancer in Pinar del Río, 2003-2006. Rev Ciencias Médicas [Internet]. 2010 Mar. 19 [cited 2025 Sep. 19];14(1):227-3. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/614

Issue

Vol. 14 No. 1 (2010)

Section

ORIGINAL ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/